Clinical characteristics of the 279 patients with de novo DLBCL
| Demographic or clinical characteristic . | FOXO1 mutated (24 patients) . | FOXO1 wild type(255 patients) . | P* . |
|---|---|---|---|
| Male, % | 67 | 64 | 0.78 |
| Age, median (range) | 66 (45-90) | 64 (16-92) | 0.27 |
| Stage, n (%) | |||
| I/II | 10 (45) | 115 (48) | 0.84 |
| III/IV | 12 (55) | 126 (52) | 0.84 |
| NA | 2 | 14 | 0.84 |
| Lactate dehydrogenase > ULN, n (%) | |||
| No | 7 (37) | 104 (48) | 0.34 |
| Yes | 12 (63) | 112 (52) | 0.34 |
| NA | 5 | 39 | 0.34 |
| ECOG performance status, n (%) | |||
| 0-1 | 13 (62) | 170 (71) | 0.37 |
| ≥2 | 8 (38) | 69 (29) | 0.37 |
| NA | 3 | 16 | 0.37 |
| Extranodal sites, n (%) | |||
| 0-1 | 20 (95) | 187 (82) | 0.14 |
| >1 | 1 (5) | 42 (18) | 0.14 |
| NA | 3 | 26 | 0.14 |
| R-IPI,†n (%) | |||
| Very good and good (0-2) | 12 (63) | 132 (61) | 0.84 |
| Poor (3-5) | 7 (37) | 85 (39) | 0.84 |
| NA | 5 | 38 | 0.84 |
| COO,‡n (%) | |||
| GCB | 11 (58) | 87 (48) | 0.42 |
| Non-GCB | 8 (42) | 94 (52) | 0.42 |
| NA | 5 | 74 | 0.42 |
| BCL2 FISH break-apart,§n (%) | |||
| Positive | 4 (33) | 43 (35) | 1.0 |
| Negative | 8 (67) | 81 (65) | 1.0 |
| NA | 12 | 131 | 1.0 |
| BCL6 FISH break-apart,§n (%) | |||
| Positive | 1 (8) | 26 (21) | 0.46 |
| Negative | 11 (92) | 95 (79) | 0.46 |
| NA | 12 | 134 | 0.46 |
| MYC FISH break-apart,§n (%) | |||
| Positive | 2 (18) | 9 (7) | 0.22 |
| Negative | 9 (82) | 115 (93) | 0.22 |
| NA | 13 | 131 | 0.22 |
| B symptoms, n (%) | |||
| Absent | 14 (67) | 157 (66) | 0.92 |
| Present | 7 (33) | 82 (37) | 0.92 |
| NA | 3 | 16 | 0.92 |
| Demographic or clinical characteristic . | FOXO1 mutated (24 patients) . | FOXO1 wild type(255 patients) . | P* . |
|---|---|---|---|
| Male, % | 67 | 64 | 0.78 |
| Age, median (range) | 66 (45-90) | 64 (16-92) | 0.27 |
| Stage, n (%) | |||
| I/II | 10 (45) | 115 (48) | 0.84 |
| III/IV | 12 (55) | 126 (52) | 0.84 |
| NA | 2 | 14 | 0.84 |
| Lactate dehydrogenase > ULN, n (%) | |||
| No | 7 (37) | 104 (48) | 0.34 |
| Yes | 12 (63) | 112 (52) | 0.34 |
| NA | 5 | 39 | 0.34 |
| ECOG performance status, n (%) | |||
| 0-1 | 13 (62) | 170 (71) | 0.37 |
| ≥2 | 8 (38) | 69 (29) | 0.37 |
| NA | 3 | 16 | 0.37 |
| Extranodal sites, n (%) | |||
| 0-1 | 20 (95) | 187 (82) | 0.14 |
| >1 | 1 (5) | 42 (18) | 0.14 |
| NA | 3 | 26 | 0.14 |
| R-IPI,†n (%) | |||
| Very good and good (0-2) | 12 (63) | 132 (61) | 0.84 |
| Poor (3-5) | 7 (37) | 85 (39) | 0.84 |
| NA | 5 | 38 | 0.84 |
| COO,‡n (%) | |||
| GCB | 11 (58) | 87 (48) | 0.42 |
| Non-GCB | 8 (42) | 94 (52) | 0.42 |
| NA | 5 | 74 | 0.42 |
| BCL2 FISH break-apart,§n (%) | |||
| Positive | 4 (33) | 43 (35) | 1.0 |
| Negative | 8 (67) | 81 (65) | 1.0 |
| NA | 12 | 131 | 1.0 |
| BCL6 FISH break-apart,§n (%) | |||
| Positive | 1 (8) | 26 (21) | 0.46 |
| Negative | 11 (92) | 95 (79) | 0.46 |
| NA | 12 | 134 | 0.46 |
| MYC FISH break-apart,§n (%) | |||
| Positive | 2 (18) | 9 (7) | 0.22 |
| Negative | 9 (82) | 115 (93) | 0.22 |
| NA | 13 | 131 | 0.22 |
| B symptoms, n (%) | |||
| Absent | 14 (67) | 157 (66) | 0.92 |
| Present | 7 (33) | 82 (37) | 0.92 |
| NA | 3 | 16 | 0.92 |
ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell like; NA, not available; ULN, upper limit of normal.
P values are for comparisons between the FOXO1 mutated and wild-type groups excluding patients where the variable is not available.
The R-IPI score ranges from 0 to 5, with higher scores indicating increased risk.23,24
COO was determined by gene expression profiling in 140 cases and by immunochemistry using the Hans Classifier in 60 cases.18-20
The presence of translocations was determined using commercial dual color “break-apart” probes from Abbott Molecular on a tissue microarray using the method described in Chin et al.41